These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 32582144)

  • 1. Complement Inhibitor Therapy for Myasthenia Gravis.
    Albazli K; Kaminski HJ; Howard JF
    Front Immunol; 2020; 11():917. PubMed ID: 32582144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
    Xiao H; Wu K; Liang X; Li R; Lai KP
    Front Immunol; 2021; 12():715036. PubMed ID: 34456922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody-Positive Generalized Myasthenia Gravis.
    Howard JF; Vissing J; Gilhus NE; Leite MI; Utsugisawa K; Duda PW; Farzaneh-Far R; Murai H; Wiendl H
    Expert Opin Investig Drugs; 2021 May; 30(5):483-493. PubMed ID: 33792453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia gravis: the role of complement at the neuromuscular junction.
    Howard JF
    Ann N Y Acad Sci; 2018 Jan; 1412(1):113-128. PubMed ID: 29266249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
    Uzawa A; Kuwabara S
    Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
    Jiao L; Li H; Guo S
    J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eculizumab for the treatment of myasthenia gravis.
    Mantegazza R; Cavalcante P
    Expert Opin Biol Ther; 2020 Sep; 20(9):991-998. PubMed ID: 32602752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapies Directed Against B-Cells and Downstream Effectors in Generalized Autoimmune Myasthenia Gravis: Current Status.
    Beecher G; Putko BN; Wagner AN; Siddiqi ZA
    Drugs; 2019 Mar; 79(4):353-364. PubMed ID: 30762205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Experience of using eculizumab in refractory myasthenia gravis].
    Stepanova SB; Karpova MI; Vasilenko AF; Domashenko MA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(7. Vyp. 2):85-90. PubMed ID: 39175245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complement associated pathogenic mechanisms in myasthenia gravis.
    Tüzün E; Christadoss P
    Autoimmun Rev; 2013 Jul; 12(9):904-11. PubMed ID: 23537510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular changes in eculizumab early responders with generalized myasthenia gravis.
    Li Y; Yi JS; Howard JF; Chopra M; Russo MA; Guptill JT
    Clin Immunol; 2021 Oct; 231():108830. PubMed ID: 34450290
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.
    Murai H; Uzawa A; Suzuki Y; Imai T; Shiraishi H; Suzuki H; Okumura M; O'Brien F; Wang JJ; Fujita KP; Utsugisawa K;
    J Neurol Sci; 2019 Dec; 407():116419. PubMed ID: 31698177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
    Datta S; Singh S; Govindarajan R
    J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Effects of the Self-administered Subcutaneous Complement Inhibitor Zilucoplan in Patients With Moderate to Severe Generalized Myasthenia Gravis: Results of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial.
    Howard JF; Nowak RJ; Wolfe GI; Freimer ML; Vu TH; Hinton JL; Benatar M; Duda PW; MacDougall JE; Farzaneh-Far R; Kaminski HJ; ; Barohn R; Dimachkie M; Pasnoor M; Farmakidis C; Liu T; Colgan S; Benatar MG; Bertorini T; Pillai R; Henegar R; Bromberg M; Gibson S; Janecki T; Freimer M; Elsheikh B; Matisak P; Genge A; Guidon A; David W; Habib AA; Mathew V; Mozaffar T; Hinton JL; Hewitt W; Barnett D; Sullivan P; Ho D; Howard JF; Traub RE; Chopra M; Kaminski HJ; Aly R; Bayat E; Abu-Rub M; Khan S; Lange D; Holzberg S; Khatri B; Lindman E; Olapo T; Sershon LM; Lisak RP; Bernitsas E; Jia K; Malik R; Lewis-Collins TD; Nicolle M; Nowak RJ; Sharma A; Roy B; Nye J; Pulley M; Berger A; Shabbir Y; Sachdev A; Patterson K; Siddiqi Z; Sivak M; Bratton J; Small G; Kohli A; Fetter M; Vu T; Lam L; Harvey B; Wolfe GI; Silvestri N; Patrick K; Zakalik K; Duda PW; MacDougall J; Farzaneh-Far R; Pontius A; Hoarty M
    JAMA Neurol; 2020 May; 77(5):582-592. PubMed ID: 32065623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting complement system to treat myasthenia gravis.
    Huda R; Tüzün E; Christadoss P
    Rev Neurosci; 2014; 25(4):575-83. PubMed ID: 24731953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myasthenia gravis: State of the art and new therapeutic strategies.
    Souto EB; Lima B; Campos JR; Martins-Gomes C; Souto SB; Silva AM
    J Neuroimmunol; 2019 Dec; 337():577080. PubMed ID: 31670062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis.
    Vu T; Meisel A; Mantegazza R; Annane D; Katsuno M; Aguzzi R; Enayetallah A; Beasley KN; Rampal N; Howard JF
    NEJM Evid; 2022 May; 1(5):EVIDoa2100066. PubMed ID: 38319212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [C5: eculizumab].
    Miyamoto K
    Brain Nerve; 2014 Oct; 66(10):1191-9. PubMed ID: 25296873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eculizumab: A Review in Generalized Myasthenia Gravis.
    Dhillon S
    Drugs; 2018 Mar; 78(3):367-376. PubMed ID: 29435915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized myasthenia gravis patients infected with COVID-19 should continue eculizumab.
    Mimori M; Komatsu T; Maku T; Mitsumura H; Iguchi Y
    Neurol Sci; 2022 Jul; 43(7):4081-4083. PubMed ID: 35364770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.